Form 8-K - Current report:
SEC Accession No. 0001213900-25-002085
Filing Date
2025-01-08
Accepted
2025-01-08 16:20:05
Documents
15
Period of Report
2025-01-08
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ea0227100-8k425_denalicap.htm   iXBRL 8-K 30680
2 PRESS RELEASE, DATED JANUARY 8, 2025 ea0227100ex99-1_denalicap.htm EX-99.1 4423
  Complete submission text file 0001213900-25-002085.txt   265070

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE decau-20250108.xsd EX-101.SCH 4171
4 XBRL DEFINITION FILE decau-20250108_def.xml EX-101.DEF 27305
5 XBRL LABEL FILE decau-20250108_lab.xml EX-101.LAB 37897
6 XBRL PRESENTATION FILE decau-20250108_pre.xml EX-101.PRE 25925
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0227100-8k425_denalicap_htm.xml XML 7470
Mailing Address 437 MADISON AVENUE 27TH FLOOR NEW YORK NY 10022
Business Address 437 MADISON AVENUE 27TH FLOOR NEW YORK NY 10022 6469785180
Denali Capital Acquisition Corp. (Filer) CIK: 0001913577 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41351 | Film No.: 25518770
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)